<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666155</url>
  </required_header>
  <id_info>
    <org_study_id>MOW-06-2020</org_study_id>
    <nct_id>NCT04666155</nct_id>
  </id_info>
  <brief_title>Cost-effectiveness of ICE With MOWOOT</brief_title>
  <official_title>Intermittent Colonic Exoperistalsis (ICE) Treatment With MOWOOT Medical Device to Treat Chronic Constipation in Adults. A Cost-effectiveness Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>usMIMA S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>County Durham and Darlington NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EIT Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>usMIMA S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to quantitatively assess the cost-effectivenes of the ICE&#xD;
      treatment with MOWOOT compared a standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess clinical effectiveness by means of quantitative and qualitative&#xD;
      variables, and the cost effectiveness by means of economic outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>Questionnaire filled at 3 time points along the study: Baseline (before treatment), Treatment (at week 12, the last week of intervention), and post-Treatment (6 months after starting the intervention, week 24)</time_frame>
    <description>Semi-quantitative assessment of the changes in quality of life respect to chronic constipation, of patients using the ICE treatment with MOWOOT compared with patients under standard of care treatment. The measure is done according to PAC-QoL questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Constipation symptoms</measure>
    <time_frame>Questionnaire filled at 3 time points along the study: Baseline (before treatment), Treatment (at week 12, the last week of intervention), and post-Treatment (at the end of follow-up, week 24)</time_frame>
    <description>Semi-quantitative assessment of the changes in symptoms of constipation of patients using the ICE treatment with MOWOOT compared with patients under standard of care treatment. The measure is done according to PAC-SYM questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic outcome</measure>
    <time_frame>At the end of intervention (week 12) and at the end of follow-up (week 24).</time_frame>
    <description>A Budget Impact Model (BIM) will be described by analysing the impact of adopting the ICE MOWOOT device instead of the Standard-of-care in England. The direct costs associated with chronic constipation to be considered within the BIM are largely expected to be the intervention costs and the cost of hospitalisation, but we will also consider any other costs across the care pathway</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Constipation - Functional</condition>
  <condition>Constipation-predominant Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Intermittent Colon Exoperistalsis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ICE Treatment with Mowoot device. 20min dayly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-of-Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard-of-care for chronic constipation for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intermittent Colonic Exoperistalsis with MOWOOT device</intervention_name>
    <description>Patients under the experimental arm of the study should place the belt of the Mowoot device on the abdomen and use it for 20 minutes every day for 12 weeks.</description>
    <arm_group_label>Intermittent Colon Exoperistalsis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation, for 12 weeks. The standard of care uses to be different in each patient: both in drugs and doses taken (laxatives) as well as in formulation/presentation (pills, laxative syrup, suppos, etc...) and even in other help to evacuation (micro or macro enemas, digitation, etc...).</description>
    <arm_group_label>Intermittent Colon Exoperistalsis</arm_group_label>
    <arm_group_label>Standard-of-Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects older than 18 years (both male and female).&#xD;
&#xD;
          2. Fulfil Rome IV criteria for Functional Constipation or Irritable Bowel Syndrome&#xD;
             Contipation (IBSC) or both&#xD;
&#xD;
          3. Subjects whose constipation aetiology is not only functional defecatory dysfunction&#xD;
             (FDD).&#xD;
&#xD;
          4. Subjects bothered by their constipation.&#xD;
&#xD;
          5. Subjects that have had no abdominal massage for at least 2 months.&#xD;
&#xD;
          6. Subjects with ability to understand the study&#xD;
&#xD;
          7. Subjects with ability to use MOWOOT or have someone to apply it.&#xD;
&#xD;
          8. Subjects that consent to participate in an informed way&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or attempt to become pregnant in the next 6 months.&#xD;
&#xD;
          2. IBSD or IBSmix: Subjects alternating constipation and diarrhoea (not due to laxative&#xD;
             use)&#xD;
&#xD;
          3. Inflammatory Bowel Disease&#xD;
&#xD;
          4. FDD as the only root cause for constipation&#xD;
&#xD;
          5. Neurogenic Bowel Dysfunction as the only root cause for constipation&#xD;
&#xD;
          6. Previous large bowel surgery&#xD;
&#xD;
          7. The presence of a stoma&#xD;
&#xD;
          8. External rectal prolapse&#xD;
&#xD;
          9. Active anorexia or bulimia&#xD;
&#xD;
         10. Mental inability to give informed consent&#xD;
&#xD;
         11. Active abdominal cancer&#xD;
&#xD;
         12. Large inguinal or umbilical hernia&#xD;
&#xD;
         13. Recent abdominal scars, abdominal wounds or skin disorders that may make abdominal&#xD;
             massage uncomfortable&#xD;
&#xD;
         14. Intra-abdominal implants (catheters, Sacral Anterior Root Stimulator (SARS),&#xD;
             medication pumps…)&#xD;
&#xD;
         15. Subjects already undertaking or have undertaken abdominal massage unless they&#xD;
             underwent a previous washout period of at least 2 months.&#xD;
&#xD;
         16. Inability to undertake the massage with the device themselves or the lack of a carer&#xD;
             willing to do it.&#xD;
&#xD;
         17. Participation in another parallel clinical trial or less than 2 months from&#xD;
             participation in a previous clinical trial&#xD;
&#xD;
         18. Subjects who do not consent to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Immaculada Herrero, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>usMIMA S.L.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Immaculada Herrero, PhD</last_name>
    <phone>+34935106653</phone>
    <email>ihf@mowoot.com</email>
  </overall_contact>
  <reference>
    <citation>Ayaş S, Leblebici B, Sözay S, Bayramoğlu M, Niron EA. The effect of abdominal massage on bowel function in patients with spinal cord injury. Am J Phys Med Rehabil. 2006 Dec;85(12):951-5.</citation>
    <PMID>17117000</PMID>
  </reference>
  <reference>
    <citation>Diego MA, Field T. Moderate pressure massage elicits a parasympathetic nervous system response. Int J Neurosci. 2009;119(5):630-8. doi: 10.1080/00207450802329605.</citation>
    <PMID>19283590</PMID>
  </reference>
  <reference>
    <citation>McClurg D, Harris F, Goodman K, Doran S, Hagen S, Treweek S, Norton C, Coggrave M, Norrie J, Rauchhaus P, Donnan P, Emmanuel A, Manoukian S, Mason H. Abdominal massage plus advice, compared with advice only, for neurogenic bowel dysfunction in MS: a RCT. Health Technol Assess. 2018 Oct;22(58):1-134. doi: 10.3310/hta22580.</citation>
    <PMID>30375324</PMID>
  </reference>
  <reference>
    <citation>Sinclair M. The use of abdominal massage to treat chronic constipation. J Bodyw Mov Ther. 2011 Oct;15(4):436-45. doi: 10.1016/j.jbmt.2010.07.007. Epub 2010 Aug 25. Review.</citation>
    <PMID>21943617</PMID>
  </reference>
  <reference>
    <citation>Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005 May;40(5):540-51.</citation>
    <PMID>16036506</PMID>
  </reference>
  <reference>
    <citation>Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol. 1999 Sep;34(9):870-7.</citation>
    <PMID>10522604</PMID>
  </reference>
  <reference>
    <citation>Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016 May;150(6):1257-61. doi: 10.1053/j.gastro.2016.03.035.</citation>
    <PMID>27147121</PMID>
  </reference>
  <reference>
    <citation>Yiannakou Y, Tack J, Piessevaux H, Dubois D, Quigley EMM, Ke MY, Da Silva S, Joseph A, Kerstens R. The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1103-1111. doi: 10.1111/apt.14349. Epub 2017 Oct 6.</citation>
    <PMID>28983926</PMID>
  </reference>
  <reference>
    <citation>Forootan M, Bagheri N, Darvishi M. Chronic constipation: A review of literature. Medicine (Baltimore). 2018 May;97(20):e10631. doi: 10.1097/MD.0000000000010631. Review.</citation>
    <PMID>29768326</PMID>
  </reference>
  <reference>
    <citation>Lämås K, Lindholm L, Engström B, Jacobsson C. Abdominal massage for people with constipation: a cost utility analysis. J Adv Nurs. 2010 Aug;66(8):1719-29. doi: 10.1111/j.1365-2648.2010.05339.x. Epub 2010 Jun 16.</citation>
    <PMID>20557387</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

